Keros Therapeutics Q4 EPS $(1.34) Beats $(1.37) Estimate
Portfolio Pulse from Happy Mohamed
Keros Therapeutics (NASDAQ:KROS) reported Q4 losses of $(1.34) per share, surpassing the analyst consensus estimate of $(1.37) by 2.19%. However, this represents a 22.94% increase in losses compared to $(1.09) per share from the same period last year.
February 28, 2024 | 9:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Keros Therapeutics reported a smaller-than-expected Q4 loss, but with an increased loss year-over-year.
While Keros Therapeutics beating the EPS estimate is positive, the increased loss year-over-year could concern investors. The mixed results make the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100